BELLUS Health’s portfolio focuses on novel therapeutics for conditions with high unmet medical need.

Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

BLU-5937 is a selective P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. BLU-5937 has shown a significant reduction in cough and no effect on taste perception in two separate preclinical models. The Company is currently performing preclinical studies on BLU-5937 to complete its package for submission of a Clinical Trial Application (CTA), expected in the second quarter of 2018. The Company plans to initiate a Phase 1 clinical study in the third quarter of 2018. Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. A recent commercial assessment performed by Torreya Insights on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.

KIACTA™ is partnered with global private equity firm Auven Therapeutics, which is currently evaluating whether to further pursue the development of KIACTA™ for the treatment of patients suffering from active pulmonary sarcoidosis. Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in pulmonary sarcoidosis. The U.S. Food and Drug Administration has cleared the investigational new drug application (IND) for this clinical Phase 2/3 study.

AMO-01 is licensed to AMO Pharma Limited, a private company focused on the treatment of central nervous system and neuromuscular diseases. AMO Pharma is preparing for a Phase 2 study to evaluate the efficacy of AMO-01 in patients suffering from intellectual disabilities in 2018. 

ALZ-801 for the treatment of Alzheimer’s disease (AD) is licensed to Alzheon Inc., a private company focused on Alzheimer's Disease and other neurodegenerative disorders. Alzheon has completed two Phase 1b clinical studies with ALZ-801 and is currently in preparation for further late-stage clinical studies.


Share this

Sign up for email alerts

Email Address *
Enter the code shown above.